Research shows buying a takeover target can result in quick returns on investments.
|
Nevro Corp. – SYM: NVRO Recent Price: $5.71
Takeover Action: The acquisition of Nevro Corp.by Globus Medical Inc. for $250 million in an all-cash transaction. As per the terms of the agreement, Globus Medical will acquire all shares of Nevro for $5.85 per share. Description: Nevro Corp., a medical device company, engages in the provision of products for patients suffering from chronic pain in the United States and internationally. The company provides HFX spinal cord stimulation (SCS) platform, which includes the Senza SCS implantable pulse generator (IPG) system, an evidence-based neuromodulation system for the treatment of chronic back and leg pain through paresthesia-free 10 kHz therapy, as well as offers Senza II and Senza Omnia SCS IPG systems. It also offers Senza HFX iQ platform, that includes HFX iQ implantable pulse generator, HFX trial stimulator, and HFX iQ patient remote, as well as HFX App, a patient remote control and the wireless trialing system; and provides sacroiliac joint fusion devices under NevroV1, NevroFix, and NevroPro brands. In addition, the company offers surpass surgical and percutaneous leads. It sells its products through its direct sales force, and a network of sales agents and independent distributors. The company was incorporated in 2006 and is headquartered in Redwood City, California. |
Conduent Incorporated – SYM: CNDT Recent Price: $4.00
Takeover Action: Reuters reported that Conduent is exploring a sale after receiving acquisition interest. The company is working with a financial adviser on its talks with potential acquirers, which include private equity firms. If the talks are successful, a deal could be signed in the coming weeks. Description: Conduent Incorporated provides digital business solutions and services for the commercial, government, and transportation spectrum in the United States, Europe, and internationally. It operates through three segments: Commercial, Government Services, and Transportation. The Commercial segment offers business process services and customized solutions to clients in various industries; and customer experience management, business operations, healthcare claims and administration, and human capital solutions. The Government segment provides government-centric business process services to the United States federal, state, local, and foreign governments for public assistance, program administration, transaction processing, and payment services; and digital payments, child support payments, government healthcare, and eligibility and enrollment solutions. The Transportation segment offers systems, support, and revenue-generating solutions to government transportation agency clients; and public safety, mobility, and digital payment solutions. This segment also provides electronic tolling, urban congestion management, and mileage-based user solutions; transit solutions; citation and permit administration, parking enforcement, and curbside demand management solutions; and computer-aided dispatch/automatic vehicle location solutions. Conduent Incorporated was founded in 2016 and is headquartered in Florham Park, New Jersey. |
Revealed: The #1 DeFi Coin Driving Financial Revolution. Experts hail this as the cornerstone of the new decentralized finance era.
While Bitcoin dominates headlines, this governance token is quietly reshaping lending markets. Experts suggest accumulating before institutional money flows in.
Access our in-depth report on the DeFi giant set to redefine finance (limited-time offer). |
SpringWorks Therapeutics, Inc. – SYM: SWTX Recent Price: $58.31
Takeover Action: Reuters reported that Merck KGaA, is in advanced talks to acquire U.S. cancer and rare diseases drugmaker Springworks Therapeutics. If the talks are successful, a deal could be signed in the coming weeks. Description: SpringWorks Therapeutics, Inc., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for underserved patient populations suffering from rare diseases and cancer. Its lead product candidate is OGSIVEO (nirogacestat), an oral small molecule gamma secretase inhibitor that is in Phase III DeFi trial for the treatment of desmoid tumors; and Nirogacestat, is also in Phase 2 clinical development as a monotherapy for the treatment of ovarian granulosa cell tumors (GCT), a subtype of ovarian cancer. The company is also involved in the development of mirdametinib, an oral small molecule MEK inhibitor that is in Phase 2b clinical trials for the treatment of neurofibromatosis type 1-associated plexiform neurofibromas (NF1-PN); mirdametinib + lifirafenib, a combination therapy that is in Phase 1b clinical trial in patients with advanced or refractory solid tumors; and mirdametinib in monotherapy and combination approaches to treat other genetically defined solid tumors, including Phase 1/2 clinical trial for the treatment of pediatric and young adult patients with low-grade gliomas. In addition, it develops Brimarafenib (BGB-3245), an oral selective small molecule inhibitor of monomeric and dimeric forms of activating BRAF mutations. The company has collaborations with BeiGene, Ltd. and GlaxoSmithKline LLC; and license agreements with Pfizer Inc. for nirogacestat and mirdametinib. It also has a license agreement with Katholieke Universiteit Leuven and the Flanders Institute for Biotechnology for a portfolio of novel small molecule inhibitors of the TEA Domain; and Dana-Farber Cancer Institute for a portfolio of novel small molecule inhibitors of Epidermal Growth Factor Receptor. The company was founded in 2017 and is headquartered in Stamford, Connecticut. |
|
|
Our mailing address is:
DC2 Publishing LLC
4260 NW 1st Avenue Suite # 55
Boca Raton, FL 33431 - 4264 Daily Insider Trades
Copyright © 2024 DC2 Publishing LLC, All rights reserved.
You're receiving this email as part of your subscription to Daily Insider Trades. For more information about our privacy practices, please review our Privacy Policy or our Terms of Use.
|
Click here to unsubscribe |
|
|
|
